Printer Friendly

WATSON PHARMACEUTICALS, INC. POSTPONES PUBLIC OFFERING

 WATSON PHARMACEUTICALS, INC. POSTPONES PUBLIC OFFERING
 CORONA, Calif., April 23 /PRNewswire/ -- Watson Pharmaceuticals,


Inc. announced that it has postponed its proposed public offering of 3,000,000 common shares due to market conditions. Allen Chao, president and CEO, said, "We will continue to monitor the market climate for health care stocks and expect to reinstate our offering when more favorable market conditions arise. The postponement will have no effect on our current business." The company filed its registration statement for the proposed offering on March 6, 1992.
 Watson is engaged in the manufacture and sale of off-patent medications and the development of advanced drug delivery systems primarily designed to enhance the therapeutic benefits of pharmaceutical compounds. The underwriting is being managed by Morgan Stanley & Co. Incorporated, Donaldson Lufkin & Jenrette Securities Corporation and Furman Selz Incorporated.
 -0- 4/23/92
 /CONTACT: Albert F. Hummel of Watson Pharmaceuticals, Inc., 814-234-7370/ CO: Watson Pharmaceuticals Inc. ST: California IN: MTC SU: OFR


AH -- NY109 -- 2020 04/23/92 14:59 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 23, 1992
Words:167
Previous Article:DUKE POWER DECLARES QUARTERLY DIVIDEND
Next Article:REPEAT HONORS FOR MERRIMAC FROM TRW WITH 1991 SUPPLIER EXCELLENCE AWARD


Related Articles
WATSON PHARMACEUTICALS ANNOUNCES FILING OF REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING
Watson Pharmaceuticals to Begin Trading on New York Stock Exchange
Watson Pharmaceuticals Receives 'Not Approvable' Letter from the FDA For Oxytrol(TM); Revises 2002 Financial Guidance Upwards.
Watson Receives FDA Approval for Generic Percocet(R) 7.5mg/325mg and 10mg/325mg; - Will Represent Watson's 12th Generic Product Launch in 2003 -.
Watson Pharmaceuticals Files Abbreviated New Drug Application For Generic AndroGel(R); - Patent Challenge Underway for Potential 180-Day Exclusivity...
Watson Receives FDA Approval for Generic Remeron(R).
Watson Launches JOLIVETTE(TM) Oral Contraceptive.
Watson Names Charles P. Slacik as Executive Vice President and Chief Financial Officer; Veteran to Run Company's Financial Operations.
Watson Launches Microgestin(R) Oral Contraceptive.
Watson Pharmaceuticals Announces Offering of Convertible Senior Debentures.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters